Market Cap 484.97M
Revenue (ttm) 0.00
Net Income (ttm) -117.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 357,700
Avg Vol 424,030
Day's Range N/A - N/A
Shares Out 66.99M
Stochastic %K 93%
Beta -0.06
Analysts Strong Sell
Price Target $22.80

Company Profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
Newcar
Newcar Jun. 9 at 5:06 PM
$ENGN When will there be the next news on this failed therapy?🤣 Waiting collapse under 1$
0 · Reply
Mr_GA
Mr_GA Jun. 4 at 2:33 PM
$ENGN https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
0 · Reply
G34
G34 Jun. 3 at 6:11 PM
$ENGN Some1 bought a loada calls today.
0 · Reply
jotu
jotu Jun. 3 at 3:10 PM
$ENGN Well its now a long hold as i keep adding about 10% from each scalp.
0 · Reply
Newcar
Newcar Jun. 3 at 2:49 PM
$ENGN In the next few months, with the confirmation of the failure of the efficacy of this therapy, it will lose at least another 50%
0 · Reply
Gunnar1
Gunnar1 May. 31 at 10:33 AM
$ENGN I'm using the weekly chart because IMO this is a long-term swing trade: Every time the price touched the blue trend line or came very close to it AND the KDJ was around 20 or below AND the RSI was at 30 or below, it subsequently rose by 150 to 260% within a timeframe of 21 to 154 days (see the price and date range marked in blue). In addition, there were smaller price increases between 50% and 114% independent of the trendline; see the price and date range marked in orange. What I’m doing now is somewhat arbitrary, but if you start with the lowest of the blue trendline-depending price increases (150%) and add the longest time period (154 days), then it could happen that at the current level — since we’re back in the range of the blue trendline — the price will be around $3.70 this autumn. Of course this is a rough estimate and there are no guarantees, but I would already be very satisfied with a 50 to 100% move. Take it with a grain of salt, I might be wrong, so you do you!
2 · Reply
BOUDIN420
BOUDIN420 May. 31 at 2:32 AM
$ENGN approaching $2 and the massive gap up as well...
0 · Reply
David_M_
David_M_ May. 29 at 3:21 PM
0 · Reply
saad545
saad545 May. 29 at 2:42 PM
$ENGN many shorts covered. Available shares to borrow increased from 3.6 Millions to 6.7 millions🔥
0 · Reply
saad545
saad545 May. 29 at 1:21 PM
$ENGN whether the drug an optimal or not, there is a debate and time will tell . The most important thing in biotech companies is cash. the net cash per share almost 4$. Very strong cash position🚀🔥
0 · Reply
Latest News on ENGN
enGene Therapeutics Transcript: AGM 2026

Jun 9, 2026, 8:30 AM EDT - 5 days ago

enGene Therapeutics Transcript: AGM 2026


enGene price target lowered to $2 from $9 at UBS

2026-05-14T15:24:03.000Z - 4 weeks ago

enGene price target lowered to $2 from $9 at UBS


enGene downgraded to Perform from Outperform at Oppenheimer

2026-05-08T16:22:56.000Z - 5 weeks ago

enGene downgraded to Perform from Outperform at Oppenheimer


enGene Therapeutics Proxy statement: Proxy filing

May 8, 2026, 8:00 AM EDT - 5 weeks ago

enGene Therapeutics Proxy statement: Proxy filing


enGene downgraded to Neutral from Buy at Guggenheim

2026-05-08T09:15:51.000Z - 5 weeks ago

enGene downgraded to Neutral from Buy at Guggenheim


enGene downgraded to Neutral from Overweight at Piper Sandler

2026-05-08T09:10:12.000Z - 5 weeks ago

enGene downgraded to Neutral from Overweight at Piper Sandler


enGene downgraded to Neutral from Buy at Guggenheim

2026-05-07T21:51:44.000Z - 5 weeks ago

enGene downgraded to Neutral from Buy at Guggenheim


enGene announces updated interim results from LEGEND cohort

2026-05-07T14:15:38.000Z - 5 weeks ago

enGene announces updated interim results from LEGEND cohort


enGene Therapeutics Transcript: Study result

May 7, 2026, 8:00 AM EDT - 5 weeks ago

enGene Therapeutics Transcript: Study result


enGene Therapeutics Slides: Study result

May 7, 2026, 8:00 AM EDT - 5 weeks ago

enGene Therapeutics Slides: Study result


enGene Therapeutics Press release: Study result

May 7, 2026, 8:00 AM EDT - 5 weeks ago

enGene Therapeutics Press release: Study result


enGene initiated with a Buy at WBB Securities

2026-04-13T11:21:48.000Z - 2 months ago

enGene initiated with a Buy at WBB Securities


enGene Therapeutics Slides: Corporate presentation

Apr 10, 2026, 7:00 AM EDT - 2 months ago

enGene Therapeutics Slides: Corporate presentation


enGene announces name change to enGene Therapeutics

2026-04-07T12:22:18.000Z - 2 months ago

enGene announces name change to enGene Therapeutics


enGene Announces Name Change to enGene Therapeutics Inc.

Apr 7, 2026, 8:00 AM EDT - 2 months ago

enGene Announces Name Change to enGene Therapeutics Inc.


enGene price target lowered to $9 from $10 at UBS

2026-03-22T14:50:06.000Z - 3 months ago

enGene price target lowered to $9 from $10 at UBS


enGene price target lowered to $30 from $33 at Oppenheimer

2026-03-11T11:56:47.000Z - 3 months ago

enGene price target lowered to $30 from $33 at Oppenheimer


enGene price target lowered to $27 from $30 at Guggenheim

2026-03-10T10:56:28.000Z - 3 months ago

enGene price target lowered to $27 from $30 at Guggenheim


enGene Therapeutics Earnings release: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 3 months ago

enGene Therapeutics Earnings release: Q1 2026


enGene Therapeutics Quarterly report: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 3 months ago

enGene Therapeutics Quarterly report: Q1 2026


enGene Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

enGene Therapeutics Slides: Corporate presentation


enGene to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:00 AM EST - 4 months ago

enGene to Participate in Upcoming Investor Conferences


enGene Therapeutics Registration statement: Registration Filing

Feb 19, 2026, 7:00 AM EST - 4 months ago

enGene Therapeutics Registration statement: Registration Filing


enGene Therapeutics Slides: Corporate presentation

Jan 9, 2026, 6:00 AM EST - 5 months ago

enGene Therapeutics Slides: Corporate presentation


enGene Therapeutics Annual report: Q4 2025

Dec 18, 2025, 4:00 PM EST - 6 months ago

enGene Therapeutics Annual report: Q4 2025


enGene Therapeutics Earnings release: Q4 2025

Dec 18, 2025, 4:00 PM EST - 6 months ago

enGene Therapeutics Earnings release: Q4 2025


enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 4:01 PM EST - 7 months ago

enGene Announces Proposed Public Offering of Common Shares


enGene Therapeutics Slides: Corporate Presentation

Nov 11, 2025, 6:00 PM EST - 7 months ago

enGene Therapeutics Slides: Corporate Presentation


enGene Therapeutics Transcript: Study Update

Nov 11, 2025, 8:00 AM EST - 7 months ago

enGene Therapeutics Transcript: Study Update


enGene Therapeutics Press release: Study Update

Nov 11, 2025, 8:00 AM EST - 7 months ago

enGene Therapeutics Press release: Study Update


enGene Therapeutics Slides: Study Update

Nov 11, 2025, 8:00 AM EST - 7 months ago

enGene Therapeutics Slides: Study Update


enGene Therapeutics Slides: Corporate Presentation

Nov 11, 2025, 7:00 AM EST - 7 months ago

enGene Therapeutics Slides: Corporate Presentation


enGene Named a BioSpace 2026 Best Places to Work Winner

Nov 4, 2025, 1:35 PM EST - 7 months ago

enGene Named a BioSpace 2026 Best Places to Work Winner


enGene Therapeutics Quarterly report: Q3 2025

Sep 11, 2025, 9:30 AM EDT - 9 months ago

enGene Therapeutics Quarterly report: Q3 2025


enGene Therapeutics Earnings release: Q3 2025

Sep 11, 2025, 9:30 AM EDT - 9 months ago

enGene Therapeutics Earnings release: Q3 2025


enGene Therapeutics Quarterly report: Q2 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q2 2025


enGene Therapeutics Earnings release: Q2 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Earnings release: Q2 2025


enGene Therapeutics Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Proxy statement: Proxy Filing


enGene Therapeutics Quarterly report: Q1 2025

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q1 2025


enGene Therapeutics Earnings release: Q1 2025

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Earnings release: Q1 2025


enGene Therapeutics Annual report: Q4 2024

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Annual report: Q4 2024


enGene Therapeutics Earnings release: Q4 2024

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Earnings release: Q4 2024


enGene Announces $60 Million Private Placement Financing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing


enGene Therapeutics Quarterly report: Q3 2024

Sep 10, 2024, 4:00 PM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q3 2024


enGene Therapeutics Earnings release: Q3 2024

Sep 10, 2024, 4:00 PM EDT - 1 year ago

enGene Therapeutics Earnings release: Q3 2024


enGene Therapeutics Quarterly report: Q2 2024

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q2 2024


enGene Therapeutics Earnings release: Q2 2024

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Earnings release: Q2 2024


enGene Therapeutics Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Proxy statement: Proxy Filing


/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:56 AM EDT - 2 years ago

/C O R R E C T I O N -- enGene Inc./


enGene Therapeutics Quarterly report: Q1 2024

Mar 11, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q1 2024


enGene Therapeutics Earnings release: Q1 2024

Mar 11, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Earnings release: Q1 2024


enGene Therapeutics Registration statement: Registration Filing

Feb 27, 2024, 7:00 AM EST - 2 years ago

enGene Therapeutics Registration statement: Registration Filing


enGene Announces Leadership Succession Plan

Feb 14, 2024, 6:45 AM EST - 2 years ago

enGene Announces Leadership Succession Plan


Newcar
Newcar Jun. 9 at 5:06 PM
$ENGN When will there be the next news on this failed therapy?🤣 Waiting collapse under 1$
0 · Reply
Mr_GA
Mr_GA Jun. 4 at 2:33 PM
$ENGN https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
0 · Reply
G34
G34 Jun. 3 at 6:11 PM
$ENGN Some1 bought a loada calls today.
0 · Reply
jotu
jotu Jun. 3 at 3:10 PM
$ENGN Well its now a long hold as i keep adding about 10% from each scalp.
0 · Reply
Newcar
Newcar Jun. 3 at 2:49 PM
$ENGN In the next few months, with the confirmation of the failure of the efficacy of this therapy, it will lose at least another 50%
0 · Reply
Gunnar1
Gunnar1 May. 31 at 10:33 AM
$ENGN I'm using the weekly chart because IMO this is a long-term swing trade: Every time the price touched the blue trend line or came very close to it AND the KDJ was around 20 or below AND the RSI was at 30 or below, it subsequently rose by 150 to 260% within a timeframe of 21 to 154 days (see the price and date range marked in blue). In addition, there were smaller price increases between 50% and 114% independent of the trendline; see the price and date range marked in orange. What I’m doing now is somewhat arbitrary, but if you start with the lowest of the blue trendline-depending price increases (150%) and add the longest time period (154 days), then it could happen that at the current level — since we’re back in the range of the blue trendline — the price will be around $3.70 this autumn. Of course this is a rough estimate and there are no guarantees, but I would already be very satisfied with a 50 to 100% move. Take it with a grain of salt, I might be wrong, so you do you!
2 · Reply
BOUDIN420
BOUDIN420 May. 31 at 2:32 AM
$ENGN approaching $2 and the massive gap up as well...
0 · Reply
David_M_
David_M_ May. 29 at 3:21 PM
0 · Reply
saad545
saad545 May. 29 at 2:42 PM
$ENGN many shorts covered. Available shares to borrow increased from 3.6 Millions to 6.7 millions🔥
0 · Reply
saad545
saad545 May. 29 at 1:21 PM
$ENGN whether the drug an optimal or not, there is a debate and time will tell . The most important thing in biotech companies is cash. the net cash per share almost 4$. Very strong cash position🚀🔥
0 · Reply
Newcar
Newcar May. 29 at 1:18 PM
$ENGN Clinical data say that this therapy works much less well than other therapies. Accept reality.
0 · Reply
saad545
saad545 May. 28 at 8:19 PM
$ENGN hahaha, it is climbing, short
0 · Reply
Newcar
Newcar May. 28 at 6:07 PM
$ENGN Failed therapy...that's why investors fled and nobody buys
0 · Reply
fantastex
fantastex May. 26 at 8:36 PM
$ENGN $4 next month
0 · Reply
24DV4NC3D
24DV4NC3D May. 26 at 5:04 PM
$ENGN ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - VOLUME >>>>> #LISTEN! <<<<< >> WAY BELOW SUPPORTS >>> PRICE GAP / DROP 5.7.26 🎯Support 2 (S2) @ 5.27 🎯Resistance 2 (S1) @ 6.18 >> CONTINUATION LIKELY! << >> INTRIGUING SETUP << ⚠️ Buyer beware :: volatility CANT MAKE THIS STUFF UP! >>>>>>> LISTEN! <<<<<<<
0 · Reply
Moneywheel
Moneywheel May. 24 at 1:28 PM
$ENGN in. Holding a few thousand shares.
0 · Reply
saad545
saad545 May. 22 at 1:40 PM
$ENGN sleeping beast🚀🔥
0 · Reply
FeliciaMath
FeliciaMath May. 22 at 11:41 AM
i may buy $ENGN today
0 · Reply
jotu
jotu May. 22 at 10:06 AM
$ENGN Cold-Chain versus Shelf-Stable Thats where the real winner is.
1 · Reply
fantastex
fantastex May. 20 at 1:35 PM
$ENGN 1.60+ today. Next week 1.70+
1 · Reply
Newcar
Newcar May. 20 at 5:36 AM
$ENGN Yes, there are more effective therapies already on the market, and others are coming. Engene should abandon this failing therapy and use the remaining cash to purchase another therapy or another clinical-stage company. The CEO must accept defeat and move on. If he continues like this, he will needlessly burn through the company's cash.
2 · Reply
jotu
jotu May. 20 at 4:34 AM
$ENGN just waiting
0 · Reply